Business
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\nLos Angeles, CA, May 07, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position, Mr. Ford will be responsible for growing Endonovo’s pipeline of marketing, content and thought leadership strategies.\n Mr. Ford has 25 years of surgical device commercial experience with leading companies, including Allergan, Ethicon, Bard & Baxter. Most recently, Mr. Ford was the U.S. Vice President of Marketing for Biom’up, where he launched the surgical hemostat HEMOBLAST Bellows™. Steven’s career includes the launch of over 50 medical devices globally as well as having participated and led over 75 product development teams. Steven holds a B.S. in Marketing from California State University. Alan Collier, Endonovo’s Chief Executive Officer, stated, \"The addition of Steven to our senior management group will help us develop alliances critical in the medical community. Steven has a very successful track record as a marketing leader in the medical device world and his knowledge and experience will bring a new perspective to our vision of leveraging our healthcare advantages for the future of SofPulse.” “Steven’s combination of medical device expertise, industry relationships, and business development experience will build upon an existing strong foundation and accelerate global adoption of SofPulse,” concluded Mr. Collier. Steven Ford stated, \"I am extremely excited to join the Endonovo team. SofPulse is an amazing technology and well positioned to become the new standard of care for post-surgical pain as a viable alternative to opioids. I look forward to introducing physicians and patients to this revolutionary technology.\" About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Compa...